Rezvani Hamid, Haghighi Shirin, Ghobakhlou Mehdi, Ataei Elnaz
Department of Hematology and Oncology, Taleghani Hospital, Shahid Beheshti University of Medical Seiences, Tehran, Iran.
Department of Endoscopy, Bou-Ali Hospital, Hamadan, Iran.
J Family Med Prim Care. 2022 Sep;11(9):5166-5169. doi: 10.4103/jfmpc.jfmpc_1678_21. Epub 2022 Oct 14.
Gastric tumors are important gastrointestinal malignancies, and the prediction of therapeutic responses and related factors are important to improve the prognosis. Hence the aim of this study was to determine the therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer.
In this prospective cohort, 13 consecutive patients with metastatic gastric cancer attending Taleghani Hospital that underwent ramucirumab + folfiri therapy were enrolled, and the therapeutic response among them was determined.
The results in this study demonstrated that initial therapeutic response was 92.3% and the Progression-free Survival (PFS) was 16.2 months (84.6%) (CI95%:13.2-19.3). The nine-month PFS was 69.2%. Total survival was 16.7 months (CI95%:13.5-19.9).
Ultimately, according to the obtained results, it may be concluded that the therapeutic response to ramucirumab + folfiri in a patient with metastatic gastric cancer is good, and the use of this regimen is recommended.
胃肿瘤是重要的胃肠道恶性肿瘤，预测治疗反应及相关因素对改善预后很重要。因此，本研究的目的是确定雷莫西尤单抗联合氟尿嘧啶、亚叶酸钙和伊立替康（FOLFIRI）方案对转移性胃癌患者的治疗反应。
在这个前瞻性队列研究中，连续纳入了13例在塔莱加尼医院接受雷莫西尤单抗联合FOLFIRI治疗的转移性胃癌患者，并确定了他们的治疗反应。
本研究结果表明，初始治疗反应率为92.3%，无进展生存期（PFS）为16.2个月（84.6%）（95%置信区间：13.2 - 19.3）。9个月的PFS为69.2%。总生存期为16.7个月（95%置信区间：13.5 - 19.9）。
最终，根据所得结果，可以得出结论，雷莫西尤单抗联合FOLFIRI方案对转移性胃癌患者的治疗反应良好，推荐使用该治疗方案。
